Stocks Industrials NAUT
NASDAQ · IndustrialsNautilus Biotechnology, Inc. (NAUT)
It posted a net loss of $58.6M. In fiscal 2025 capital spending exceeded operating cash flow by $52M. At September 30, 2026 it held $10.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Nautilus Biotechnology, Inc.
- Net worth
- Nautilus Biotechnology, Inc. has a market value (market cap) of $292.1M at the latest share price, and shareholders' equity of $116.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $50.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Nautilus Biotechnology, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Nautilus Biotechnology, Inc. does
Nautilus Biotechnology, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker NAUT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$59M | -$0.47 | -$52M |
| 2024 | n/a | -$70.8M | -$0.56 | -$61.3M |
| 2023 | n/a | -$63.7M | -$0.51 | -$54.2M |
| 2022 | n/a | -$57.9M | -$0.46 | -$48.1M |
| 2021 | n/a | -$50.3M | -$0.60 | -$41.5M |
| 2020 | n/a | -$15.6M | -$0.54 | -$14.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Nautilus Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Activist stake changed SCHEDULE 13D/A
- October 27, 2026Quarterly report 10-Q · period to September 30, 2026Revenue was $234K; diluted EPS -$0.12 versus -$0.11.
- October 27, 2026
- September 11, 2026Activist stake changed SCHEDULE 13D/A
- September 11, 2026
- September 11, 2026
- August 28, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- July 28, 2026
- July 28, 2026
Insider trades
What the people running Nautilus Biotechnology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 2, 2026 | AH Equity Partners Bio II, L.L.C.10% owner | Soldindirect | 4,615,974 | $10.8M |
| June 2, 2026 | AH Equity Partners Bio II, L.L.C.10% owner | Soldindirect | 384,026 | $902.5K |
| March 4, 2026 | Patel Sujal MCEO, President, and Secretary, Director, 10% owner | Bought | 25,000 | $65.2K |
Who owns NAUT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Parag Mallick13D, may seek influence | 17.6% | March 4, 2026 |
| Sujal Patel13D, may seek influence | 16.3% | March 4, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 93 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Perceptive Advisors LLC | 11,634,211 | -960,000 |
| a16z Capital Management, L.L.C. | 9,063,054 | -8,590,863 |
| Cercano Management LLC | 7,172,985 | 0 |
| BlackRock, Inc. | 2,687,226 | +2,499,555 |
| Vanguard Capital Management LLC | 2,549,979 | +4,382 |
| Comprehensive Financial Management LLC | 2,207,619 | 0 |
| Citadel Advisors LLC | 1,896,192 | new |
| Geode Capital Management, LLC | 1,265,535 | +662,011 |
| Clearstead Advisors, LLC | 892,787 | -1,436,997 |
| Susquehanna International Group, Llp | 890,949 | new |
| Barclays PLC | 725,321 | +651,996 |
| Renaissance Technologies LLC | 690,514 | +424,814 |
| Jpmorgan Chase & Co | 614,177 | new |
| State Street Corp | 559,508 | +343,238 |
| Dimensional Fund Advisors LP | 475,844 | +146,721 |
| Northern Trust Corp | 381,234 | +274,223 |
| Vanguard Fiduciary Trust Co | 353,093 | +47,567 |
| Vanguard Portfolio Management LLC | 337,748 | new |
| Marshall Wace, Llp | 265,582 | -54,300 |
| Qube Research & Technologies Ltd | 257,346 | +177,723 |
Insiders
2 insiders reported holding 11,338,606 shares in total, about $26M at the last price.
| Holder | Shares |
|---|---|
| Patel Sujal MCEO, President, and Secretary, Director, 10% owner | 10,366,721 |
| AH Equity Partners Bio II, L.L.C.10% owner | 971,885971,885 held indirectly |
Questions about NAUT
What does Nautilus Biotechnology, Inc. do?
Nautilus Biotechnology, Inc. is a company in the Industrials sector, listed on NASDAQ as NAUT. Its shares trade on NASDAQ under the ticker NAUT.
What is Nautilus Biotechnology, Inc.'s net worth?
Nautilus Biotechnology, Inc. has a market value (market cap) of $292.1M at the latest share price, and shareholders' equity of $116.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nautilus Biotechnology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $58.6M.
When did Nautilus Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 3, 2026.
When is Nautilus Biotechnology, Inc.'s next earnings report?
Nautilus Biotechnology, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NAUT with
Follow NAUT
Get an email when Nautilus Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nautilus Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.